DUBLIN, Ireland, December 11, 2013 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) announces that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) relating to its previously announced tender offer by a wholly owned subsidiary of Shire for all outstanding shares of ViroPharma Incorporated (NASDAQ: VPHM) expired at 11:59 p.m., Eastern U.S. time, on December 10, 2013. The expiration of the HSR waiting period satisfies one of the conditions to the tender offer. The tender offer remains subject to certain other conditions set forth in the offer to purchase, including the termination of review or approval of the transaction by the United Kingdom Office of Fair Trading and the satisfaction of the minimum tender condition. The tender offer is scheduled to expire at 6:00 p.m., Eastern U.S. time, on Thursday, December 26, 2013, unless the tender offer is extended. NOTES TO EDITORS Shire enables people with life-altering conditions to lead better lives. Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs. We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal, Internal Medicine and Regenerative Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas. http://www.shire.com ADDITIONAL INFORMATION AND WHERE TO FIND IT This announcement is for informational purposes only and does not constitute an offer to purchase or a solicitation of an offer to sell ViroPharma common stock. The offer to buy ViroPharma common stock is being made pursuant to a tender offer statement (including the offer to purchase, letter of transmittal and other related tender offer materials) filed by Shire Pharmaceutical Holdings Ireland Limited (SPHIL) and a subsidiary of SPHIL with the U.S. Securities and Exchange Commission (SEC) on November 25, 2013. In addition, on November 25, 2013, ViroPharma filed with the SEC a solicitation/recommendation statement on Schedule 14D-9 with respect to the tender offer. Investors and security holders are urged to read both the tender offer statement and the solicitation/recommendation statement as they contain important information, including the terms and conditions of the tender offer, that should be read carefully before any decision is made with respect to the tender offer. Investors and security holders may obtain a free copy of these materials and other documents filed by SPHIL and ViroPharma with the SEC at the website maintained by the SEC at http://www.sec.gov/. The tender offer statement and related materials, and the solicitation/recommendation statement, may also be obtained for free by contacting the information agent for the offer, MacKenzie Partners, Inc., at (212) 929-5500 or toll-free at (800) 322-2885. Copies of these materials and any documentation relating to the tender offer are not being, and must not be, directly or indirectly, mailed or otherwise forwarded, distributed or sent in, into or from any jurisdiction where to do so would be unlawful.